Beam Therapeutics announced that the interim results of its BEACON Phase 1/2 study of risto‑cel (BEAM‑101) were published in the April 1 issue of the New England Journal of Medicine. The publication, released on April 1 2026, reports data from 31 patients with sickle cell disease who received the gene‑edited autologous stem‑cell therapy.
The study demonstrates a durable increase in fetal hemoglobin (HbF) above 60 % and a reduction of sickle hemoglobin (HbS) below 40 %, with no severe vaso‑occlusive crises observed after engraftment. These results confirm the safety profile expected from myeloablative conditioning and show rapid engraftment and sustained non‑sickling hemoglobin levels comparable to sickle cell trait.
Risto‑cel’s base‑editing platform, which avoids double‑strand DNA breaks, positions the therapy competitively against other SCD gene therapies such as Vertex/CRISPR’s Casgevy and Bluebird Bio’s Lyfgenia. The therapy has already received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, supporting a streamlined regulatory pathway and the company’s plan to file a biologics license application by year‑end 2026.
Beam Therapeutics’ financial position provides a strong runway for continued development. As of December 31 2025, the company held $1.25 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2027 or 2028 and to support the anticipated BLA submission.
Management highlighted the strategic advantages of base editing. Dr. Matthew M. Heeney, the corresponding author of the NEJM publication, noted that risto‑cel “has the potential to meaningfully alter the pathophysiology of the disease and improve outcomes for patients with SCD.” CEO John Evans emphasized that base editing could reduce manufacturing cycles, accelerate product delivery, and mitigate the genotoxic risks associated with traditional CRISPR approaches.
The publication of these data marks a significant milestone for Beam Therapeutics, reinforcing the clinical promise of risto‑cel and strengthening the company’s position in the evolving sickle cell disease therapeutic landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.